Mylan Investigative Site #100 — Greenfield, Wisconsin

Mylan Investigative Site #100 is a clinical research site located in Greenfield, Wisconsin, United States 53228.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Mylan Investigative Site #100 has participated in 1 clinical trials.

Therapeutic areas: Asthma.

Sponsors: Mylan Pharma UK Ltd..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Greenfield

Browse all research sites in Wisconsin · View every site in Greenfield

• GSK Investigational Site
• Research Site
• Allergy Asthma & Sinus Center, S.C.
• Advanced Pain Management
• Allergy Asthma and Sinus Center
• Allergy Asthma & Sinus Center
• Allergy Asthma and amp Sinus Ctr S C
• Allergy, Asthma Sinus Center, SC
• BCN Research, LLC
• Novartis Investigative Site
• Aurora Health Center - Greenfield
• Center for Neurological Disorders G

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mylan Investigative Site #100?

Mylan Investigative Site #100 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mylan Investigative Site #100 conducted?

Mylan Investigative Site #100 has 1 clinical trials on record. Their work covers Asthma.

Is Mylan Investigative Site #100 accredited by Crixeo Clinical Trials?

Mylan Investigative Site #100 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mylan Investigative Site #100?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.